Results 41 to 50 of about 20,576 (195)
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper +9 more
wiley +1 more source
Ranibizumab For Diabetic Macular Edema Refractory To Multiple Prior Treatments [PDF]
, 2016 Purpose: Diabetic macular edema can be refractory to multiple treatment modalities. Although there have been anecdotal reports of ranibizumab showing efficacy when other modalities provided limited benefit, little has been published on treatment for ...
Ciulla, Lauren +4 more
core +2 more sources
The impact of systemic long‐term medications for the development of age‐related macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä +3 more
wiley +1 more source
Al-Azhar Assiut Medical Journal, 2019 Background Diabetic macular edema (DME) is a common cause of blindness and visual impairment in diabetic patients, which can affect the quality of life.
Abd El-Magid M Tag El-Din
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco +2 more
wiley +1 more source
Therapeutic Advances in OphthalmologySummary What is this summary about? This is a summary of a publication about the PHOTON study, which was published in The Lancet . Diabetic macular edema (DME) is a serious and common complication of diabetes, with an estimated global prevalence of 5.5 ...
David M. Brown +22 more
doaj +1 more source
Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting [PDF]
, 2017 Background: Multiple criteria decision analysis (MCDA) has appeared as a methodology to address limitations of economic evaluation in health technology assessment (HTA), however there are limited empirical evidence from real world applications.
Angelis, Aris +3 more
core +2 more sources
Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies +8 more
wiley +1 more source
The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review [PDF]
, 2017 The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect ...
Bracha, Peter +4 more
core +1 more source
Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
BMC Ophthalmology, 2018 Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid +9 more
doaj +1 more source